Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
about
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.First- and second-line therapy for metastatic urothelial carcinoma of the bladderDown-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancerUse of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].Clinical Impact of Consolidative and Salvage Radiotherapy for Lymph Node Metastasis in Upper Urinary Tract Urothelial Carcinoma.Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysisUpdate on chemotherapy in the treatment of urothelial carcinoma
P2860
Q33394158-15FC5ED4-E109-4829-B5F8-3EC2B5AA2E5EQ33394213-AD149F85-E36F-45F3-8882-E42CB9EF78C2Q33403679-978D5483-5CDD-4B12-B982-D4CC953C6288Q33408261-37574F94-164A-4FE4-A607-16E4396042A4Q33431220-4C4CEFC4-59E3-4E9A-A5F4-362996A5C6ECQ34541463-1D8468BA-9B5D-4151-AC5E-3B0D17BD3C1FQ35618447-4CAA3B0E-ED85-4970-9394-D56AD5BC8657Q36192053-EE4EDD09-2D03-4187-9369-608FFAB1BCE8Q36947812-F2AF5C20-3A07-4DC8-9473-AE0BC963459FQ37283592-6C7E5559-9AF2-4893-8377-62A1CD069FA2Q37284023-D1BA9AC6-37E4-4443-AFAF-11F6C7A32583Q37896172-FA0FE626-A2FA-48DB-8319-866CC6E77971Q38155201-A9AD464F-3FF6-4A11-A8A5-1D97E7E2801CQ38612831-FE083A85-A7CF-4D0A-9FC4-D4904BF0DC7EQ38798645-D4AAAD65-8A9A-4BE8-B949-54916F73B52CQ40714083-8BF36A9C-4A70-4E89-B173-FA18CC10E9F1Q44373064-34341C7B-F547-4A89-AC3D-F0D560A33BF4Q44750072-75A08127-3ABD-43BD-993C-B7FE6F9224A8Q47103525-EEA08696-5FCB-406B-97F0-D2A29FFC3FD3Q53462584-1F45F232-2D65-405F-80D8-1E20812BC383Q55287396-C767AFF2-523B-4789-87A6-6BF203A1BD26Q57073547-9861F884-EB60-427A-9AC0-6766F5BCDD70Q58694390-665F93F4-6E05-4FFB-A257-F6B3501B1190
P2860
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@ast
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@en
type
label
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@ast
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@en
prefLabel
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@ast
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@en
P2093
P1476
Gemcitabine and paclitaxel che ...... cisplatin-based chemotherapy.
@en
P2093
Akira Miyajima
Jun Nakashima
Ken Nakagawa
Kunimitsu Kanai
Mototsugu Oya
Takashi Ohigashi
P2860
P2888
P304
P356
10.1007/S10147-008-0779-X
P50
P577
2008-12-18T00:00:00Z